Development of lipid nano particles RNA vaccine against hepatitis B surface antigens of hepatitis B virus | ||||
| International Journal of Health Sciences (Egypt) | ||||
| Volume 2, Issue 2, April 2024, Page 74-83 PDF (909.14 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ijhegy.2023.203375.1018 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Mohammed M Kassab  
| ||||
| Instructor of microbiology,immunology,faculty of pharmacy,Cairo university,Egypt Specialist of pharmacology, toxicology and clinical pharmacy. | ||||
| Abstract | ||||
| Background: Hepatitis B is a severe overwhelming infection. Hepatitis B is a viral infection that attacks liver cells, causing inflammation and damage to the liver. Infection is usually confined to hepatocytes. Over 2 billion people have been infected with hepatitis B virus at some point. Immunity arises from natural infection or from administration of vaccines. Purpose of the survey: Development of an RNA vaccine against lethal hepatitis B surface antigen of hepatitis B virus. Research type: screening experiment research. Methodology: In our study, we victimized bioinformatics to engineer an RNA vaccine from hepatitis B surfactant antigen. Lipid nanoparticles with a particle size of 150 nanometers were utilized as a vaccine delivery system. Result: The vaccine has shown an efficacy of 81% in preclinical animal studies and an efficacy of 79% in human clinical studies (Phase 1/2 clinical trials). It exhibited moderate biological activity and had fewer side effects than other standard vaccines. The effect lasted for a long time. Conclusion: Our RNA-HBV vaccine was a promising prophylactic vaccine against fatal hepatitis B virus infection. | ||||
| Keywords | ||||
| Hepatitis B virus; vaccine; RNA; infection | ||||
|
Statistics Article View: 61 PDF Download: 9 |
||||
